New light shone on inflammatory cell death regulator
19 June 2020 Walter and Eliza Hall Institute researchers have made significant advances in understanding the inflammatory cell death regulatory protein MLKL and its role in disease. In a trio of studies published today in the journal Nature Communications,…
Dr Larry Marshall reappointed as CSIRO Chief Executive
22 June 2020 The Board of Directors of CSIRO, Australia’s national science agency, is pleased to reappoint Dr Larry Marshall as Chief Executive for a further three years. Dr Marshall joined CSIRO in 2015. David Thodey AO, Chair…
Grey Innovation: NOTUS Ventilator Program Update
22 June 2020 Ten weeks ago, the Hon Karen Andrews MP, Minister for Industry, Science and Technology announced the $31.3m Grey Innovation supply contract for 2,000 emergency invasive ventilators. Named after the Greek God of Southern Wind, the…
Burnet vaccine modelling shaping global policies for hepatitis B elimination
18 June 2020 Cost-effective ways to improve the delivery and management of hepatitis B (HBV) vaccine, identified in new Burnet Institute research, have attracted interest from global policymakers including the World Health Organization (WHO) and Gavi, the international vaccine alliance. The…
Medtronic and Foxconn Partner to Increase Ventilator Production
18 June 2020 Companies Aim to Produce 10,000 Puritan Bennett™ 560 Ventilators Together in the United States Over the Next Year Partnership Established after Medtronic Announces Ventilator Open Source Initiative Medtronic plc (NYSE:MDT) and Foxconn Industrial Internet, a…
Chasing COVID-19: CSIRO scientists find fast, cheaper way to find outbreaks in our wastewater
19 June 2020 Tracking community outbreaks of COVID-19 through wastewater can happen faster, using more cost-effective tests, according to new research published by the Australian national science agency, CSIRO. The new research builds on the world’s first peer-reviewed…
Noxopharm COVID-19 Trial Program to Commence in Europe
19 June 2020 NOX proceeding with its COVID-19 clinical program in Europe while discussions with FDA continue Phase 1 trial aiming to confirm proof-of-principle and safety of Veyonda® in a timely and cost-effective way before committing to a…
Cynata Announces Ethics Approval and Expedited Regulatory Pathway for Phase 3 Osteoarthritis Clinical Trial
18 June 2020 Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to report important progress towards the commencement of recruitment in the Phase 3 clinical trial of CYP-004, its CymerusTM mesenchymal stem cell…
Medtronic Self-Expanding Venous Stent Demonstrates Favorable Outcomes in Patients with Venous Outflow Obstruction
16 June 2020 Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first-ever results from the ABRE clinical study assessing the safety and effectiveness of the investigational Abre™ venous self-expanding stent system in subjects with…
Global Expansion Continues: Sienna enters Greek market with hTERT IVD
19 June 2020 Aenorasis S.A. appointed exclusive distributor in Greece and Cyprus Aenorasis has net annual turnover of €34.9 million and was awarded the Boussias Communications Golden Distinction Healthcare Business Award in Greece (2019) Bladder cancer is globally…
Monash University Announces Research Collaboration With Janssen To Tackle Coeliac Disease
17 June 2020 Monash University has signed a multi-year research collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to advance the understanding of the immune mechanisms underpinning Coeliac Disease and inform…
COVID-19 Impact On The MTP Sector – New Reports Launched
18 June 2020 To better understand the burden of the COVID-19 lockdown on the medical technology, biotechnology and pharmaceutical (MTP) sector in Australia, MTPConnect recently undertook research, in partnership with L.E.K. Consulting, to explore the impacts of the…
